Get the Stockscreener App
2.07
0.96%
-0.02
After Hours:
2.07
Proqr Therapeutics N V stock is traded at $2.07, with a volume of 368.45K.
It is down -0.96% in the last 24 hours and up +13.11% over the past month.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
See More
Previous Close:
$2.09
Open:
$2.06
24h Volume:
368.45K
Relative Volume:
0.35
Market Cap:
$292.12M
Revenue:
$15.53M
Net Income/Loss:
$-52.71M
P/E Ratio:
-4.1194
EPS:
-0.5025
Net Cash Flow:
$-59.00M
1W Performance:
-9.61%
1M Performance:
+13.11%
6M Performance:
+21.76%
1Y Performance:
-13.39%
1-Day Range:
$2.06
$2.11
1-Week Range:
$2.06
$2.29
52-Week Range:
$1.33
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.07 | 320.34M | 15.53M | -52.71M | -59.00M | -0.5025 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | Oppenheimer | Outperform |
| Apr-29-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-10-25 | Upgrade | Citigroup | Neutral → Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
CureVac NV (CVAC) Peer Comparison – Compare with Others - Value Research
ProQR to Participate in Upcoming Investor Conferences in September 2026 - markets.businessinsider.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ProQR Therapeutics N.V.ADR Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
ProQR Therapeutics NV (PRQR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Certain Warrants of ProQR Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - marketscreener.com
Certain Common Stock of ProQR Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - marketscreener.com
ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts (NASDAQ:PRQR) - Seeking Alpha
ProQR Therapeutics starts with Buy rating on st... - Pluang
Price to sales forward of ProQR Therapeutics N.V. – FWB:0PQ - TradingView
PRQR Looks 1.8% Undervalued on GF Value™ at $2.45 - GuruFocus
PRQR Initiates Coverage by B of A Securities -- Price Target Ann - GuruFocus
ProQR a new buy at BoA on RNA-editing platform - Seeking Alpha
ProQR Therapeutics (NASDAQ:PRQR) Earns Buy Rating from Analysts at Bank of America - MarketBeat
BofA Securities initiates ProQR stock with buy on liver therapy By Investing.com - Investing.com India
BofA Securities initiates ProQR stock with buy on liver therapy - Investing.com
ProQR (PRQR) Levels: Climbs 3.26% to $2.22 in the Latest Session; Key Range - vinanet.vn
HC Wainwright Expects Lower Earnings for ProQR Therapeutics - MarketBeat
ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus
Equities Analysts Set Expectations for PRQR FY2030 Earnings - MarketBeat
H.C. Wainwright reiterates ProQR stock rating on platform data By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates ProQR stock rating on platform data - Investing.com India
ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Hold at Wall Street Zen - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Announces Earnings Results - MarketBeat
ProQR: Q2 Earnings Snapshot - KING5.com
symbol__ Stock Quote Price and Forecast - CNN
ProQR Therapeutics NV earnings beat by €0.03, revenue topped estimates - Investing.com Nigeria
ProQR Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
ProQR Therapeutics NV reports results for the quarter ended June 30Earnings Summary - TradingView
ProQR Reports Higher Revenue but Ongoing Losses in Second Quarter 2026 Results - TipRanks
ProQR Announces Second Quarter 2026 Operating and Financial Results - The Manila Times
ProQR Therapeutics Reports First Clinical Validation of Axiomer RNA Editing Platform, Positive AX-0810 Data and Upcoming Pipeline Milestones - Quiver Quantitative
ProQR Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ProQR Therapeutics NV expected to post a loss of 11 cents a shareEarnings Preview - TradingView
ProQR Therapeutics (PRQR) Slips 3.5% as Shares Test Key Support ZoneReversal Trade - dars.gov.et
ProQR Therapeutics NV (PRQR) Stock News Today - TradingKey
ProQR Therapeutics NV (PRQR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBIT forward of ProQR Therapeutics N.V. – MUN:0PQ - TradingView
ProQR Therapeutics (PRQR) CEO de Boer Daniel Anton Buys 200,000 Shares, Signaling Confidence - GuruFocus
ProQR Therapeutics (PRQR) Surges 7% to $1.83 as Buyers Defend Key SupportAnalyst Downgrade Signals - vinanet.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Proqr Therapeutics Insider Bought Shares Worth $353,960, According to a Recent SEC Filing - marketscreener.com
ProQR Therapeutics (PRQR) CEO boosts stake with 200,000-share buy - Stock Titan
ProQR Therapeutics N.V. Revenue Breakdown – NASDAQ:PRQR - TradingView
ProQR Therapeutics (PRQR) to Announce Earnings on Thursday - MarketBeat
Van Herk Investments Files Petition with the Enterprise Chamber of the Amsterdam Court of Appeal Against ProQR Therapeutics - marketscreener.com
ProQR Therapeutics (NASDAQ:PRQR) Director Bart Filius Buys 150,000 Shares - MarketBeat
ProQR Therapeutics N.V. Revenue Breakdown – LS:A12B97 - TradingView
ProQR Therapeutics NV (PRQR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PRQR|ProQR Therapeutics NV|Price:1.720|Chg%:-0.060 - TradingKey
PRQR|ProQR Therapeutics NV|Price:1.730|Chg%:+0.010 - TradingKey
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Proqr Therapeutics N V Stock (PRQR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Filius Bart | Director |
Jul 17 '26 |
Buy |
1.72 |
150,000 |
257,925 |
300,000 |
| de Boer Daniel Anton | Chief Executive Officer |
Jul 09 '26 |
Buy |
1.74 |
150,000 |
261,000 |
300,000 |
| de Boer Daniel Anton | Chief Executive Officer |
Jul 07 '26 |
Buy |
1.59 |
150,000 |
238,500 |
150,000 |
| Filius Bart | Director |
Jun 26 '26 |
Buy |
1.54 |
150,000 |
231,000 |
150,000 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):